Published: 1 December 2022
Publications
Recent approvals: new active ingredients or new indications
Prescriber Update 43(4): 58December 2022
For the period 16 July to 15 October 2022.
Recent approvals of medicines with new active ingredients
Trade name (active ingredient) | Dose form: strength(s) | Therapeutic area |
---|---|---|
Cresemba (isavuconazonium) | Powder for injection: 200mg Capsule: 100mg |
Antifungal agent for treatment of invasive aspergillosis, mucormycosis |
Spy Agent Green (indocyanine green) | Powder for injection: 25mg | Fluorescence imaging agent |
Entyvio (vedolizumab) | Powder for injection: 300mg | Ulcerative colitis, Crohn’s disease |
Nubeqa (darolutamide) | Tablet: 300mg | Non-metastatic castration resistant prostate cancer |
Evusheld (cilgavimab + tixagevimab)* | Solution for injection: 100mg/mL | Pre-exposure prophylaxis of COVID-19 |
Approved medicines with new indications
There were no approved medicines with new indications for the period 16 July 2022 to 15 October 2022.
See the Medsafe website for: